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Abstract
Background: DNA microarray analysis has great potential to become an important clinical tool
to individualize prognostication and treatment for breast cancer patients. However, with any
emerging technology, there are many variables one must consider before bringing the technology
to the bedside. There are already concerted efforts to standardize protocols and to improve
reproducibility of DNA microarray. Our study examines one variable that is often overlooked, the
timing of tissue acquisition, which may have a significant impact on the outcomes of DNA
microarray analyses especially in studies that compare microarray data based on biospecimens
taken in vivo and ex vivo.
Methods: From 16 patients, we obtained paired fine needle aspiration biopsies (FNABs) of breast
cancers taken before (PRE) and after (POST) their surgeries and compared the microarray data to
determine the genes that were differentially expressed between the FNABs taken at the two time
points. qRT-PCR was used to validate our findings. To examine effects of longer exposure to
hypoxia on gene expression, we also compared the gene expression profiles of 10 breast cancers
from clinical tissue bank.
Results: Using hierarchical clustering analysis, 12 genes were found to be differentially expressed
between the FNABs taken before and after surgical removal. Remarkably, most of the genes were
linked to FOS in an early hypoxia pathway. The gene expression of FOS also increased with longer
exposure to hypoxia.
Conclusion: Our study demonstrated that the timing of fine needle aspiration biopsies can be a
confounding factor in microarray data analyses in breast cancer. We have shown that FOS-related
genes, which have been implicated in early hypoxia as well as the development of breast cancers,
were differentially expressed before and after surgery. Therefore, it is important that future studies
take timing of tissue acquisition into account.
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Background
DNA microarray analysis is an evolving high-throughput
molecular technology that enables scientists to survey
thousands of genes simultaneously. The resulting gene
profiles (GPs) have been employed for the investigation
of complex multi-factorial diseases such as breast cancer.
In breast cancer, GPs have been shown to correlate with
many clinically relevant clinico-pathological parameters,
to prognosticate survival and predict treatment responses
to specific chemotherapeutic regimens [1-9]. Despite its
potential in clinical applications, one of the main hurdles
to be overcome is the reproducibility of DNA microarray
data due to several variables that may influence the
results. These variables include different protocols used in
tissue handling, RNA extractions and amplifications,
microarray platforms and statistical analyses. Efforts are
underway to standardize and validate the procedure. One
such important initiative is the Microarray Quality Con-
trol (MAQC) project launched by the US Food and Drug
Administration (FDA) [10]. It compared microarray data
using identical RNA samples on three different DNA
microarray platforms from independent laboratories.
They demonstrated that in well designed studies under
strict conditions, the microarray technology is highly
reproducible. The FDA has recently approved several
microarray platforms for clinical use.
In this study, we examined the hypothesis that timing of
tissue acquisition, either taken pre- or post-operatively (in
vivo or ex vivo, respectively), is one of the important varia-
bles that may influence DNA microarray results. Many
studies have failed to report or control for this variable. It
is particularly important when comparing studies
designed to evaluate gene profiles of in vivo specimens
such as those obtained in the neo-adjuvant setting, to
more traditional studies that evaluate gene profiles in ex
vivo specimens from surgery or tissue banks.
Fine needle aspiration biopsies (FNABs) have been used
successfully to obtain cancer cells for DNA microarray
studies [11-17]. As compared with core biopsy or surgi-
cally resected specimens, FNAB specimens appear to
enrich for epithelial cells with comparable yield in RNA
[11,12]. Additional advantages of using FNABs include
the ability to obtain specimens for microarray analyses
without significant compromise of standard histological
assessments, and the ability to assess cytology of these
FNAB specimens.
In this study, we compared GPs from FNABs taken pre-
operatively and post-operatively in 16 patients to deter-
mine the effects of timing on the microarray data. To iden-
tify genes that may potentially confound with gene
signatures in DNA microarray data.
Methods
Patients and fine needle aspirate biopsies (FNAB)
Sixteen patients with known palpable invasive breast can-
cer planned to have surgery for the primary tumors and
nodal assessment, were recruited into the study at Princess
Margaret Hospital (Toronto, On). This study was
approved by our institutional research ethics committee,
University Health Network Research Ethics Board, and all
patients gave written informed consent. In each of the 16
patients, the first FNAB was taken before surgery (PRE)
and the second FNAB was taken immediately after the sur-
gical removal of the tumor in the operating room (POST).
FNABs were obtained using a 25-gauge needle on a 10-cc
syringe, with the needle passing the tumor 10 to 20 times.
Two needle biopsies were utilized for each time point. An
aliquot of the FNAB was placed into 15 ml of CytoLyt
(Cytyc Corp; Marlborough, MA) for cytological analyses
by the cytopathologist (SB). The remaining cells in the
FNABs were placed into 500 μl of RNA extraction lysis
buffer (Qiagen; Valencia, CA) and were immediately lysed
by repeatedly passing the suspension through the FNAB
needle and then quick frozen to -80°C and stored for later
processing. Table 1 summarizes the clinico-pathological
features of the 16 patients, FNAB cytology and RNA yields
from each of the two time points.
Tissue bank specimens
For comparison purposes, we obtained 10 fresh frozen
random invasive breast cancer specimens from our insti-
tutional tissue bank (University Health Network
Biobank). The tissue bank specimens were annotated with
clinico-pathology information and taken from patients
with breast cancers larger than 2 cm who had surgery at
our institution.
RNA extraction and amplification
Frozen FNAB lysates were thawed in a 37°C water bath for
15 min, and RNA was extracted using RNAeasy Micro kit
(Qiagen). 15–20 mg of tissue bank specimens were placed
into 700 μL of RNA extraction lysis buffer (Qiagen) and
then homogenized using a PRO 200 rotor stator homoge-
nizer (PRO Scientific Inc; Oxford, CT). The RNA was
extracted using RNAeasy Lipid mini kit (Qiagen). Qualita-
tive analyses of the RNA samples were determined using
the Agilent 2100 Bioanalyzer RNA 6000 LabChip kit (Agi-
lent Technologies; Palo Alto, CA). In many cases the RNA
yields from the FNABs were less than 2 μg (Table 1), to
standardize the RNA processing, we amplified all the RNA
samples using the MessageAmp aRNA amplification kit, a
T7 based linear amplification (Ambion; Austin, Tx) in one
round. 100–1000 ng of total RNA was used as a starting
amount for amplification according to the manufacturer's
instructions.BMC Cancer 2008, 8:277 http://www.biomedcentral.com/1471-2407/8/277
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Microarray hybridization
The amplified RNA species from FNABs and an amplified
Universal Human Reference RNA (Stratagene; La Jolla,
CA) were directly labeled using cyanine 3 and cyanine 5
fluorescent dyes for microarray hybridization. Direct labe-
ling of the sample on glass slide Microarrays was pre-
formed according to the protocol given by the University
Health Network Microarrays Centre (University Health
Network, Toronto, On) [18]. Briefly, first-strand cDNA
synthesis was performed with Superscript II (Invitrogen;
Carlsbad, CA) in the presence of cyanine 3-dCTP or cya-
nine 5-dCTP (Amersham; Little Chalfont, UK) from 5 to
10 μg of RNA. The generated cDNA probes were then puri-
fied and denatured. The labeled targets were hybridized to
UHN h19k cDNA microarrays (single spotted cDNA
microarray chips comprising of 19,008 characterized and
unknown human ESTs) manufactured at the University
Health Network Microarray Centre. Scanning of the
microarrays was achieved by using the Axon Scanner
4000A (Molecular Devices Corp.; Sunnyvale, CA) to
obtain 16 bit TIFF image files.
Microarray and statistical analysis
GenePix 6.0 (Molecular Devices Corp.) was used to ana-
lyze the TIFF image files of the h19k cDNA microarrays for
quantitation. A total of 64 microarray image files of pre
(PRE) and post-operative (POST) samples with dye-swap
replicates from the 16 patients were analyzed. The raw
data in GenePix report (GPR) format were directly trans-
ferred into Acuity 4.0 (Molecular Devices Corp.) for anal-
ysis. After Lowess slide normalization of the GPR files, any
uninformative microarray data were flagged and filtered.
The dye-swap signal ratios were inverted before the data of
the replicate were combined. Probes with minimal
changes in expression level (Log2 ratio >= 1 or <= -1 in not
more than 2 tumors) were removed, resulting in a list of
4,056 probes (National Center for Biotechnology Infor-
mation Gene Expression Omnibus depository [19], acces-
sion number GSE12072). Then t-Test and hierarchal
clustering analyses were used to select differentially
expressed genes. Subsequent statistical analyses were car-
ried out using SPSS 13.0 (SPSS, INC., Chicago, IL). Pear-
son Correlation was used to measure the expression level
similarities between the replicated microarrays as well as
between the microarray and real-time quantitative RT-
PCR (qRT-PCR) examinations. PathwayAssist 3.0 (Strata-
gene) was used to determine the gene product interac-
tions, based on a reference database (Ariadne Inc.
Rockville, MD), updated in October 2007. Downloaded
annotation files of UHN h19k cDNA microarray were
updated by using UniGene Human Build 211 (GPL7025).
Real-time quantitative RT-PCR(qRT-PCR)
The expression levels of selected genes in the microarray
data were validated by performing qRT-PCR on the ampli-
fied RNA samples that were used for the microarray
hybridization. qRT-PCR was performed using Gene Amp
9700 sequence detector (Applied Biosystems, Foster City,
CA). Pre-designed Taqman gene expression assays
(Applied Biosystems) were used for each gene using prim-
Table 1: Tumor clinico-pathological features, cytology, and RNA yields of the patients.
Patient No. Tumor 
Type
Tumor Size
(cm)
Tumor 
Grade
ER* PR* HER2* Positive 
Nodes
PRE Total 
RNA
(μg)
PRE Tumor 
Cell
(%)
POST Total 
RNA
(μg)
POST 
Tumor Cell
(%)
1 IDC 2.8/2.6 2 & 3 + + + 2–26 9.6 >99 15.4 >99
2 IDC 1.9 3 + + - 0/12 0.8 >99 1.4 >99
3 IDC 2 3 + + - 1–17 0.4 >99 9.8 >99
4 IDC 1.6 3 + + - 1–4 1.9 >99 1.4 >99
5I D C3 2 + - - 0 / 1 6 0 . 2> 9 91 * *
6 IDC 15 3 + + - 29/32 0.5 >99 1.8 >99
7 IDC 4.5 3 - - + 0/11 7.6 >99 30.4 >99
8 IDC 1.6 2 + + - 0/16 1.4 >99 3.7 >99
9 IDC 1.7 3 - - - 1–18 2 >99 1.1 >99
10 IDC 2.2/1.0 3 - - + 2–17 7.5 >99 3.4 >99
11 IDC/
lobular
6.5 2 + + - 8–15 1.5 >99 3.2 >99
12 IDC 2.5 3 - - - 8–25 1.3 ** 12.4 >99
13 IDC 4 2 + + - 2–20 4.2 >99 8.5 >99
14 IDC 6.5 2 - - + 1–12 9.5 >99 3.2 >99
15 IDC 2.1 2 + + - 0/3 1.2 >99 9.6 50
16 IDC 3.4 2 + + - 0/3 1.9 >99 0.4 >99
ER, estrogen receptor; PR, progesterone receptor; HER2, Her2/neu receptor status; IDC, invasive ductal carcinoma; ILC, invasive lobular 
carcinoma.*ER, PR, and HER2 status as reported on standard surgical pathology reports were determined by immunohistochemistry, or by 
fluorescent in situ hybridization (FISH) for HER2 according to our institutional standard of practice. ** Cytology from FNABs of patient 5 POST and 
12 PRE could not be determined due to low cellularity in the cytologic fractions.BMC Cancer 2008, 8:277 http://www.biomedcentral.com/1471-2407/8/277
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ers away from the 3' end sequence of the transcript. For all
qRT-PCR reactions, standard concentration of assays and
Universal TaqManPCR Mastermix (Applied Biosystems)
were used. The Sequence Detection Software (Applied
Biosystems) was used to obtain the amplification plot to
quantify gene expression values using the cycle threshold
method. Human universal Reference RNA (Stratagene)
was used as the calibrator sample, and the housekeeping
gene GAPDH served for the standardization of the indi-
vidual PCR reactions.
Results
Comparison of Pre and Post-operative microarray profiles
After data filtering (see Methods section), a list of 4,056
cDNA probes remained informative. We then preformed
a t-test on the log2 ratio of each cDNA probe to identify
genes discriminating PRE and POST samples from each
patient by using a P-value < 0.05 detection level. Then a
hierarchical clustering analysis was used to separate the
relatively homogeneous clusters. As a result, 14 cDNA
probes representing 12 unique genes and one expressed
sequence tag of an unknown gene (Fig. 1A) were identi-
Differential gene expression pattern of breast cancers between FNABs taken pre-operatively (PRE) and post-operatively  (POST) Figure 1
Differential gene expression pattern of breast cancers between FNABs taken pre-operatively (PRE) and post-
operatively (POST). (A) Hierarchical clustering pattern of expression of 14 cDNA probes between PRE and POST FNABs 
(p < 0.05, t-test). Rows represent cDNA probes and columns represent FNAB samples. "PRE" and "POST" correspond to pre 
and post-operative biopsies for the respective samples. The expression level is depicted according to the color scale (bottom) 
which represents the Log2 ratio changes of the samples relative to the human universal reference RNA (Stratagene). Grey 
squares indicate missing or filter-excluded data. (B) Validation of FOS gene expression in cDNA microarray using qRT-PCR. 
qRT-PCR data shown are averages of duplicate measurements. The columns correspond to FOS expression data in the micro-
array and qRT-PCR from PRE and POST specimens. The rows represent the corresponding specimens. Each cell in the matrix 
represents the expression level of Log2 ratio for microarray or Log ratio for qRT-PCR relative to the human universal refer-
ence RNA (Stratagene).
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fied (see Additional file 1). Two cDNA probes correspond-
ing to FOS were found to be most significant in
differentiating PRE and POST specimens (P = 0.002 and
0.006).
Biological relationships of differentially expressed genes 
from Pre and Post-operative microarray profiles
The biological relationships of the 12 genes differentiat-
ing PRE and POST GPs were further investigated using
PathwayAssist 3.0 software (Stratagene). We searched
using the shortest paths between the genes to make up
their biological interaction network. The software recog-
nized 11 of the 12 genes. Nine out of the 11 genes formed
a network and they were linked directly or indirectly to
FOS (Fig. 2). qRT-PCR was used to validate the expression
level of FOS in each of the FNAB specimens (Fig. 1B).
Trends in FOS expression with prolonged ischemia
FOS is known to be expressed in hypoxic conditions [20],
and we hypothesized that what we observed in the higher
expression of multiple members of the FOS network was
related to the length of ischemic exposure prior to biopsy.
To test this hypothesis, we compared the expression levels
of FOS in 10 surgical specimens of invasive breast cancers
that were left in an ischemic state for at least 30 minutes
before freezing (Figure 3) to our FNAB specimens. The
cDNA microarray analyses showed that FOS expression
levels in the tissue samples were indeed higher than that
in PRE and POST FNAB specimens (P = 0.000023, p =
0.000071) (Fig 3A and 3B) with a trend of higher FOS
expression with longer ischemic time. Figure 3C showed
the concordance between the microarray expression levels
of the two FOS probes and the qRT-PCR data in tissue
samples.
Pathway linkage analysis of the differentially expressed genes between PRE and POST FNABs Figure 2
Pathway linkage analysis of the differentially expressed genes between PRE and POST FNABs. Nine genes (blue 
halo), out of 11 differentially expressed genes, including FOS were linked in the analysis (PathwayAssist 3.0) and formed a net-
work. The layout of cellular location for the proteins is graphically presented.
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Discussion
DNA microarray is an evolving technology that has prom-
ise in diagnosing and prognosticating clinical outcomes of
breast cancers [1-9]. This has led to increased efforts to
standardize this technology [10]. Implementing standards
for microarray technology involves controlling all the
potential confounding variables systematically, from sam-
ple collection to microarray data management, to ensure
reliability of test results. Our study examined one such
variable that has not been addressed in previous studies,
which is the timing of tissue acquisition for DNA microar-
ray analyses.
In our study, we elected to use FNAB for tissue acquisition.
When compared to core biopsy, FNAB appeared to be less
invasive for the participating patients, and the cell speci-
mens collected were mostly malignant cells (99% table 1).
The latter finding is consistent with a study by Symmans
et al. [11] in which they reported enrichment of epithelial
cells in FNAB as compared with core biopsy specimens.
FOS expression in PRE, POST and tissue specimens of breast cancers Figure 3
FOS expression in PRE, POST and tissue specimens of breast cancers. (A) The expression levels of two FOS probes 
in microarray data of PRE and POST FNAB from 16 cases of invasive breast cancers, and tissue specimens from 10 invasive 
breast cancers. (B) FOS expression changes among the different specimens for array probe 1 (PRE vs. POST, P = 0.002 and 
PRE vs. tissue, P = 0.000023) and array probe 2 (PRE vs. POST, P = 0.006 and PRE vs. tissue, P = 0.000071). (C) Comparison of 
FOS expression levels between microarrays and qRT-PCR data for tissue specimens of breast cancers. The correlation coeffi-
cients between FOS expression level detected by qRT-PCR and two array data for tissue specimens are 0.86 (P = 0.0015) and 
0.79 (P = 0.0063).
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The loose cells collected appeared to improve RNA extrac-
tion from small biopsy specimens as it facilitates cell lysis
without the need for tissue homogenization and with
minimal contamination of other cellular components.
Although the RNA yield is variable (0.2 to 30.4 ug, table
1), overall, sufficient quantity and quality of RNA can be
obtained for the purpose of molecular profiling when
amplified. Several studies have assessed the fidelity of T7
based linear RNA amplifications and have shown that lin-
ear amplification with as little as 100 ng-1000 ng is highly
representative [21-23]. Due to variable RNA yields from
FNABs, the qRT-PCR component of this study was per-
formed on amplified RNA which may introduce 3' bias as
a result of the amplification process. However, we did not
observe significant 3' bias as we were able to correlate our
microarray data even though the qRT-PCR primers were
selected from sequences away from the 3' end of the tran-
scripts. A number of gene expression profiling studies
have also been able to validate their data using amplified
RNA in qRT-PCR [16,24-29].
Gene profiles generated from the FNABs taken before and
after surgery in general were reproducible except for the 12
genes related to FOS. Since FOS has previously been asso-
ciated with ischemic conditions [20,30,31], we hypothe-
sized that this observation was due to the duration of
exposure to hypoxia. We then tested the hypothesis by
demonstrating a much higher FOS expression level, using
DNA microarray and qRT-PCR, in fresh frozen tissue spec-
imens that were exposed to a longer ischemic time (figure
3A, B and 3C). Our pre-operative tumor FNABs were per-
formed on tumors that were still in vivo and the specimens
were immediately placed in lysis buffer and snap frozen
after the biopsy. The post-operative FNABs were obtained
similarly but on ex vivo tumors after surgical excision in
the operating room. In the case of tissue bank specimens,
fresh surgical specimens were delivered to the pathology
laboratory before freezing and therefore consistently
experienced hypoxia much longer than the FNAB speci-
mens. Müller et al [20] reported that hypoxia can induce
FOS expression as early as 15 minutes exposure to
hypoxia but plateaus at about 30 minutes. This was con-
sistent with our findings which demonstrated a higher
level of FOS expression with longer ischemic time (Fig. 3).
Hypoxia can induce two classes of hypoxia-related genes:
immediate early genes (induced within minutes) and
delayed response genes (arising slowly over hours) [32].
FOS is an example of an immediate early gene, it com-
plexes with JUN to form the activator protein-1 transcrip-
tion factor complex (AP-1) which regulates gene
expression in response to hypoxia, and it has been known
to be associated with regulation of cell cycle activities such
as cell proliferation, differentiation, transformation, and
apoptotic cell death [30]. In classic hypoxia pathways acti-
vated through Hypoxia-Inducible Factor-1α (HIF1α), the
response to hypoxia is delayed [32], these genes include
vascular endothelial growth factor (VEGF) [33], erythrpoi-
etin (EPO) [34], neuronal nitric oxide synthase (NOS)
[35], endothelin 1 (EDN1) [36], lactate dehydrogenase A
(LDHA) [37] glycolytic enzymes and glucose transporters
such as glycolytic enzymes aldolase A(ALDA) and phos-
phoglycerate kinase 1 (PGK1) [38], Many of these
hypoxia-related pathways have been implicated in
adverse cancer biology and may be linked to chronic
hypoxia and tumor necrosis [39].
From the 4,056 informative genes in our microarray data,
we were not able to detect changes in gene expressions
related to other hypoxic pathways before and after the sur-
gery. Out of the twelve differentially expressed genes, only
FOS had potential interactions with HIF pathway. FOS
interacts with HIF1α via AP-1 complex [32,40]. It is possi-
ble that in surgical specimens, the expressions of immedi-
ate early genes induced by hypoxia, including FOS, were
elevated minutes after removal of the tumors. However,
expressions of delayed response genes, such as those acti-
vated by HIF1α, were not significantly altered because
they required a longer time to elicit any significant
change. This would be consistent with our findings of ele-
vated gene expressions in FOS-related hypoxia pathway
but not in other hypoxic pathways mediated through
HIF1α. However, given the limitations of our study, we
are not able to rule out all the changes in other hypoxic
pathways. After data filtering (see Methods section), some
of the critical genes in these pathways, including HIF1α
and VEGF, were not represented in our microarray data.
Further study is needed to draw concrete conclusion on
the other hypoxic pathways from our observations.
In addition to the effects of hypoxia, there was a possibil-
ity that the physiological responses to general anesthesia
or the stress of the surgery could have caused the observed
changes in tumor gene expression, if this was the case, the
mechanism is currently unknown and it would appear to
be mediated through FOS-related pathway.
Interestingly, FOS has been associated with breast cancer
in a number of studies [41-44]. FOS is involved in the
expression of genes associated with malignant progres-
sion such as metalloproteases that degrade the extracellu-
lar matrix that may facilitate invasion and metastasis [45-
47]. Most previous microarray studies utilized banked tis-
sue [1-4] and hypoxia-related genes may influence the
result of the clustering analyses by affecting the ranking of
differentially expressed genes. For example, Sotiriou et al.
[7] reported that FOS was one of the genes that separated
basal 1 and 2 subtypes of breast cancers, although it is dif-
ficult to know if the group could draw a similar conclu-
sion if they used in vivo specimens in their study instead.BMC Cancer 2008, 8:277 http://www.biomedcentral.com/1471-2407/8/277
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In contrast to the study by Sotiriou et al., Perou et al. [4]
examined gene expression profiling on breast cancer tis-
sue (unpublished data cited in [4]), they excluded a clus-
ter of genes including FOS simply because the authors
believed that these genes were induced by prolonged han-
dling of samples following surgical resection. It is quite
possible that early hypoxic genes such as FOS may affect
the ranking of some genes in previously published gene
signatures. Hence, timing of tissue acquisition must be
considered when interpreting microarray data.
Conclusion
Our study demonstrated that expression of early hypoxic
genes can be influenced by the timing of tissue acquisi-
tion. Notably FOS, which is one of the most differentially
expressed genes between the two time points was impli-
cated in both hypoxia [20,31,32,40] and other breast can-
cer gene signatures [4,7,41]. Our study suggested that the
timing of sample collection may confound microarray
data analysis and therefore must be taken into considera-
tion when designing future studies.
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